Fractyl Health Inc., a metabolic therapeutics company, has announced advancements in its Rejuva Smart GLP-1 pancreatic gene therapy platform, specifically with its clinical candidate RJVA-001 targeting type 2 diabetes (T2D). The company revealed new preclinical data at the American Diabetes Association's 85th Scientific Sessions, demonstrating that a single dose of Rejuva was well-tolerated in healthy mice and effectively prevented obesity and diabetes in models exposed to a high-fat diet. These findings support the progression of RJVA-001 toward first-in-human studies, with preliminary clinical data expected in 2026, pending regulatory authorization. The study results have already been presented.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。